Fabimycin
From Wikipedia, the free encyclopedia
 | |
| Names | |
|---|---|
| IUPAC name
(E)-3-(7-amino-8-oxo-5,6,7,9-tetrahydropyrido[2,3-b]azepin-3-yl)-N-methyl-N-[(3-methyl-1-benzofuran-2-yl)methyl]prop-2-enamide | |
| Identifiers | |
3D model (JSmol) |
|
| ChemSpider | |
PubChem CID |
|
| |
| |
| Properties | |
| C23H24N4O3 | |
| Molar mass | 404.470 g·mol−1 |
Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa).
| |
Fabimycin is an newly developed antibiotic candidate which is effective against gram-negative bacterias, an unusually problematic class of bacteria that uses thicker cell walls and molecular efflux pumps to protect themselves by preventing the antibiotics reaching inside the cells.[1][2]
Global deaths attributable to antimicrobial resistance (AMR) numbered 1.27 million in 2019. That year, AMR may have contributed to 5 million deaths and one in five people who died due to AMR were children under five years old.[3] The European Centre for Disease Prevention and Control calculated that in 2015 there were 671,689 infections in the EU and European Economic Area caused by antibiotic-resistant bacteria, resulting in 33,110 deaths. Most were acquired in healthcare settings.[4]